Jun 12, 2015 • 8:12 am EDT Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)
Jun 5, 2015 • 8:05 am EDT Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
Jun 1, 2015 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference
May 18, 2015 • 8:30 am EDT Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab™ for the Treatment of Cystic Fibrosis
May 14, 2015 • 8:05 am EDT Corbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board
May 13, 2015 • 7:05 am EDT Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update
May 4, 2015 • 7:05 am EDT Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015
Apr 22, 2015 • 7:05 am EDT Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab™ Clinical Program
Apr 16, 2015 • 7:35 am EDT Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market